U.S. Markets close in 1 hr 17 mins

Pfizer Inc. -- Moody's: Pfizer's acquisition of Array is credit negative

Moody's Investors Service commented that Pfizer Inc.'s acquisition of Array BioPharma Inc. ("Array") for $11.4 billion is credit negative. There is no impact on Pfizer's ratings, including the A1 long-term rating and the Prime-1 commercial paper rating, or on the stable outlook. For additional information please refer to Moody's issuer comment on Pfizer available on www.moodys.com.